Heron Therapeutics (NASDAQ:HRTX) Releases Earnings Results, Hits Expectations

Heron Therapeutics (NASDAQ:HRTX) posted its earnings results on Monday. The biotechnology company reported ($0.03) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.03), FiscalAI reports. The company had revenue of $35.25 million during the quarter, compared to the consensus estimate of $37.50 million. Heron Therapeutics had a negative return on equity of 237.56% and a negative net margin of 14.55%.

Heron Therapeutics Stock Performance

Shares of HRTX stock opened at $0.37 on Wednesday. The firm has a market capitalization of $71.02 million, a price-to-earnings ratio of -3.12 and a beta of 1.65. The company has a current ratio of 2.49, a quick ratio of 1.51 and a debt-to-equity ratio of 24.35. The business’s 50-day moving average price is $0.33 and its 200-day moving average price is $0.66. Heron Therapeutics has a 12 month low of $0.26 and a 12 month high of $1.57.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on HRTX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Thursday, October 15th. Wall Street Zen upgraded Heron Therapeutics to a “sell” rating in a research report on Saturday, August 8th. Zacks Research upgraded Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, August 3rd. Finally, HC Wainwright lowered Heron Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 11th. Three equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Heron Therapeutics has an average rating of “Reduce” and an average price target of $2.00.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and marketing medicines for acute care and oncology supportive care. Its products are designed to address unmet needs such as postoperative pain and chemotherapy-induced nausea and vomiting. The company’s portfolio includes ZYNRELEF, an extended-release solution combining bupivacaine and meloxicam for the management of postoperative pain in adults. Heron also markets CINVANTI, an injectable formulation of aprepitant used as part of a combination regimen to help prevent acute and delayed nausea and vomiting associated with highly or moderately emetogenic cancer chemotherapy.